Garrahan Hospital recently reported on the positive results of the first scientific study on the effectiveness of cannabis oil in children suffering from refractory epilepsy in Argentina. 80% of patients had a positive response with a significant reduction in the number of health issues. The overall response rate to the medication was highly satisfactory and expectations were greatly exceeded.
Garrahan Hospital recently reported on the positive results of the first scientific study on the effectiveness of Argentina’s medical cannabis oil in children suffering from refractory epilepsy in Argentina.
80% of patients had a positive response with a significant reduction in the number of health issues. The overall response rate to the medication was highly satisfactory and expectations were greatly exceeded.
Argentina’s medical cannabis study exceeds expectations
With the sanction of law 27,350 on medical cannabis in 2017, Argentina’s medical cannabis industry opened the way for scientific research on this subject.
Aphria Inc., through its subsidiary in Argentina ABP SA, has been working to bring Argentina’s medical cannabis manufactured with pharmaceutical standards and at an affordable price.
Of the 49 patients with sufficient follow-up, 39 of them had a positive response. The initial group average of 959 crises per month (about 30 per day) decreased to 381 crises per month (13 per day), a decrease of 60%. Hospital officials said that “expectations were greatly exceeded.”
“We at Aphria Inc., provider of Argentina’s medical cannabis oil used in this study, share the joy of improving the quality of life of these children. We also congratulate the team at Garrahan Hospital that is conducting this study for their dedication and professionalism,” the company stated.
Aphria Inc. leads study on Argentina’s medical cannabis
A key step was taken in October 2018 when Garrahan Hospital began receiving the 1,500 units of the 50-milliliter Aphria CBD 25: 1 (formerly known as Rideau) medical cannabis oil for a study of the most severe cases of refractory epilepsy in pediatrics.
To carry out this study, Aphria Inc. provided a monitoring kit for the diagnosis of epilepsy, and now Garrahan is the only public hospital in the country with this technology.
The program will last 27 months and has the approval of the Ministry of Health of the Nation. Because of its size, it is the most ambitious program ever carried out worldwide for children with refractory epilepsy.
Argentina’s medical cannabis study is at the forefront of efforts in education and research in the niche, but there is still a lot of research that remains.
Aphria Inc. and ABP will continue to support patients participating in the Garrahan Hospital pediatric clinical trial and any other patients who need legal access to medical cannabis products as part of their treatment.
It is important to highlight the sanction of Resolution 133/2019 according to which patients with refractory epilepsy and their respective social works can consolidate medical prescriptions to reduce the cost of importing and shipping the product.
Argentina’s medical cannabis faces some issues
ABP has created a specialized team that can assist patients and families with the import process as part of the treatment for refractory epilepsy.
The company continues to be committed to Argentina’s medical cannabis market on issues of social responsibility and to support scientific research so that more patients and doctors have access to complementary treatments with medical cannabis.
Aphria Inc. has a global presence and employs over 1,000 people worldwide and since 2014 has supported nearly 75,000 medical cannabis patients across Canada. The Canadian greenhouse production facility covers over 2,389,588 square feet.
The key to the medical cannabis industry
In Latin America, Aphria Inc. is present in Colombia and Jamaica and is looking at other Southern Cone countries.
However, Argentina’s medical cannabis market is key to consolidating its regional strategy given its business climate, high-quality labor and market potential.
With appropriate legislation, the country could bring about medical cannabis similar to how the country experienced the soy industry boom. This would involve significant growth in skilled labor and solid investment in infrastructure and services.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in El Cronista, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.